Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease

被引:6
|
作者
Ren, Fang-Ping [1 ]
Chen, Qi [1 ]
Yao, Shan-Shan [2 ]
Feng, Lin [3 ]
Xue, Xin-Ying [1 ]
Zhao, Wei-Chao [4 ]
Wang, Dong [3 ]
Zhao, Zhi-Ling [3 ]
Gu, Si-Wei [5 ]
Li, Ting [3 ]
Shen, Ya-Wen [1 ]
Gao, Lan [1 ]
Zang, Xue-Lei [1 ]
Bao, Xin-Yu [6 ]
Tong, Zhao-Hui [3 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China
[4] PLA Strateg Support Force Med Ctr, Beijing, Peoples R China
[5] Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China
[6] Weifang Med Coll, Weifang, Peoples R China
关键词
Anti-melanoma differentiation-associated gene 5; Dermatomyositis; Interstitial lung disease; Lymphocyte subsets; Prognostic; MYOSITIS-SPECIFIC AUTOANTIBODIES; AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; PNEUMONIA; RISK;
D O I
10.1186/s12890-023-02706-y
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Objectives To examine the characteristics of blood lymphocyte subsets in dermatomyositis-interstitial lung disease (DM-ILD) inflicted patients with positive anti-melanoma differentiation-associated gene 5 (anti-MDA5), as well as its prognosis value in this set of patients.Methods Data were retrospectively collected from 253 DM-ILD patients from three hospitals in China between January 2016 to January 2021. Patients were grouped into anti-MDA5 antibody positive group (MDA5(+) DM-ILD) and anti-MDA5 antibody negative group (MDA5(-) DM-ILD) based on myositis-specific autoantibody test results. Demographic characteristics, lymphocyte subsets patterns and other clinical features were compared between the two groups. The association of lymphocyte subsets with 180-day mortality was investigated using survival analysis in MDA5(+) DM-ILD.Results Out of 253 eligible patients with DM-ILD, 59 patients were anti-MDA5(+) and 194 were anti-MDA5(-). Peripheral blood lymphocyte count, CD3(+) count, percentage of CD3(+), CD3(+)CD4(+) count, and CD3(+)CD8(+) count was lower in MDA5(+) DM-ILD than in MDA5(-) DM-ILD- (all P < 0.001) as well as CD3(-)CD19(+) count (P = 0.04). In MDA5(+) DM-ILD, CD3(+)CD8(+) count <= 49.22 cell/mu L (HR = 3.81, 95%CI [1.20,12.14]) and CD3-CD19(+) count <= 137.64 cell/mu L (HR = 3.43, 95%CI [1.15,10.24]) were independent predictors of mortality. CD3(+)CD8(+) count <= 31.38 cell/mu L was associated with a higher mortality risk in all DM-ILD patients (HR = 8.6, 95%CI [2.12,31.44]) after adjusting for anti-MDA5 and other clinical characteristics.Conclusion Significant lymphocytes decrease was observed in MDA5(+) DM-ILD patients. CD3(+)CD8(+) cell count was associated with worse prognosis in both MDA5(+) DM-ILD and all DM-ILD patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Multidisciplinary approach to anti-MDA5 antibody-positive dermatomyositis associated with rapidly progressive interstitial lung disease
    Witkowska, Anna Barbara
    Cowley, Sharon
    Dempsey, Philip
    Stack, John
    BMJ CASE REPORTS, 2022, 15 (03)
  • [22] Serum uric acid, a potential biomarker for interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis
    Xie, Huaiya
    Fan, Junping
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 69
  • [23] Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients
    Xue, Yuan
    Zhang, Junmei
    Deng, Jianghong
    Kuang, Weiying
    Wang, Jiang
    Tan, Xiaohua
    Li, Chao
    Li, Shipeng
    Li, Caifeng
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (11) : 1499 - 1501
  • [24] Anti-MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality
    Soni, Dipekka
    Maniscalco, David
    Veeraraghavan, Srihari
    Cheeley, Justin
    Khosroshahi, Arezou
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [25] Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease disguising as anti-synthetase syndrome
    Tanaka, Nao
    Terao, Chikashi
    Nakayama, Yoichi
    Sasai, Tsuneo
    Umezawa, Natsuka
    Yagyu, Yuriko
    Ito, Kanae
    Koike, Ryuji
    Nakashima, Ran
    Hatta, Kazuhiro
    Mizoguchi, Fumitaka
    RHEUMATOLOGY, 2021, 60 (03) : E104 - E106
  • [26] Rapidly Progressive Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis
    Thomas, M.
    Deshpande, P.
    Tran, L.
    Sampath, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [27] Clinical Features and Prognostic Factors for Dermatomyositis-Associated Interstitial Lung Diseases with Anti-MDA5 Antibody
    Fujisawa, T.
    Hozumi, H.
    Yasui, H.
    Suzuki, Y.
    Karayama, M.
    Furuhashi, K.
    Enomoto, N.
    Nakamura, Y.
    Inui, N.
    Suda, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [28] Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report
    De Backer, Eva
    Gremonprez, Felix
    Brusselle, Guy
    Depuydt, Pieter
    Van Dorpe, Jo
    Van Haverbeke, Carole
    Goeminne, Pieter C.
    Derom, Eric
    ACTA CLINICA BELGICA, 2018, 73 (06) : 413 - 417
  • [29] Increase in Mitochondrial Mass of Lymphocyte Subsets in Anti-MDA5 and TIF1-γ-Positive Dermatomyositis Patients
    Li, Xiaomeng
    Ma, Qingqing
    Huang, Yuan
    Cheng, Linlin
    Liu, Yongmei
    Li, Haolong
    Zhan, Haoting
    Zhang, Fengchun
    Liu, Yudong
    Li, Yongzhe
    IMMUNOLOGICAL INVESTIGATIONS, 2024, 53 (08) : 1381 - 1396
  • [30] Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis
    Ho So
    Victor Tak Lung Wong
    Virginia Weng Nga Lao
    Hin Ting Pang
    Ronald Man Lung Yip
    Clinical Rheumatology, 2018, 37 : 1983 - 1989